Vectura Group PLC is staying positive despite having decided to stop development of a drug-device combination to treat severe uncontrolled asthma after a late-stage study failure.
The Phase III trial of VR475, which consists of budesonide delivered by the UK company's proprietary nebulizer inhalation system, did...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
